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Abstract
Background: Quantifying isoniazid resistant (INH-R) tuberculosis (TB) is important because isoniazid resistance reduces the
probability of treatment success, may facilitate the spread of multidrug resistance, and may reduce the effectiveness of
isoniazid preventive therapy (IPT).
Methodology/Principal Findings: We used data reported to the World Health Organization between 1994–2009 to
estimate the INH-R burden among new and retreatment TB cases. We assessed geographical and temporal variation in INH-
R and reported levels in high HIV prevalence countries ($2%) to understand implications for IPT. 131 settings reported INH-
R data since 1994. A single global estimate of the percentage of incident TB cases with INH-R was deemed inappropriate
due to particularly high levels in the Eastern European region where 44.9% (95% CI: 34.0%, 55.8%) of incident TB cases had
INH-R. In all other regions combined, 13.9% (95% CI: 12.6%, 15.2%) of incident cases had INH-R with the lowest regional
levels seen in West/Central Europe and Africa. Where trend data existed, we found examples of rising and falling burdens of
INH-R. 40% of high HIV prevalence countries reported national data on INH-R and 7.3% (95% CI: 5.5%, 9.1%) of cases in these
settings had INH-R.
Conclusions/Significance: Outside the Eastern European region, one in seven incident TB cases has INH-R, while this rises to
nearly half within Eastern Europe. Many countries cannot assess trends in INH-R and the scarcity of data from high HIV
prevalence areas limits insight into the implications for IPT. Further research is required to understand reasons for the
observed time trends and to determine the effects of INH-R for control of TB.
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Introduction
In 2009, the World Health Organization (WHO) estimated that
there were 9.4 million incident cases of tuberculosis (TB) and 1.7
million deaths due to TB [1]. While the incidence of TB is
decreasing in five of the six WHO regions [1], the emergence of
multi-drug resistant (MDR) TB (TB which is resistant to at least
isoniazid and rifampin) [2] threatens to derail advances made
against TB. MDRTB can take up to two years or more to treat
with drugs that are less potent, more toxic and much more
expensive [2]. The most recent WHO summary of the global
burden of drug resistant TB was released in 2010 and reported the
highest levels recorded for MDRTB, with an estimated 3.6% of
incident TB resistant to the two most important first line
antibiotics [2].
Although combined resistance to essential first-line antibiotics
(i.e. MDR) poses the greatest risk to patients, resistance to
isoniazid alone is also important. Isoniazid is the cornerstone of
any first-line treatment. Compared with other TB drugs, it has
the most potent early bactericidal activity [3,4] and rarely causes
adverse events [5]. Loss of effectiveness of this drug compromises
both the preventive therapy and treatment of disease. Recent
systematic reviews and meta-analyses confirmed that isonaizid
monoresistance is associated with reduced probability of success-
ful treatment outcomes for individuals receiving standard
treatment and an increased risk of acquiring additional drug
resistance [6,7]. In addition, individuals infected with isoniazid
resistant strains of M. tuberculosis are unlikely to benefit from
Isoniazid Preventive Therapy (IPT), which, in the absence of
resistance, is effective in reducing the risk of progression to
disease after infection [8]. Given the growing role of IPT in
addressing the challenge of HIV-associated TB [9], measuring
the burden of isoniazid resistant (INH-R) TB in populations with
high prevalence of HIV is important for understanding if
resistance will compromise the expected benefits of this
intervention.
In this paper, we use all data from population-representative
surveys and surveillance on INH-R reported to the WHO between
1994 and 2009. We estimate the burden of INH-R regionally and
nationally and examine trends where data are available.
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Data collection
In 1994, the International Union Against Tuberculosis and
Lung Diseases and the Stop TB Department at the WHO formed
a Global Project on Anti-Tuberculosis Drug Resistance in order to
estimate the worldwide burden of drug resistant TB. Through this
initiative, national and sub-national data from surveillance activity
(in countries where continuous drug sensitivity testing of all
incident TB cases is performed) and periodic population
representative surveys (in countries where drug sensitivity tests
are not routinely performed) have been reported to the WHO in
standard formats permitting the generation of regional and global
estimates of the burden and trends of resistant disease. The details
of these surveillance and survey activities have been provided
elsewhere [2,10]. Data in this analysis include all reports of
surveillance and survey activities made to the Global Project
relating to the period 1994–2009. All of the data used here have
been published previously [2,11,12,13,14] (although never previ-
ously analysed to address these questions) and have been cleared
for publication by individual countries.
Statistical analysis
We examined three categories of isoniazid resistance: resistance
to isoniazid (in the absence or presence of any other drug
resistance), resistance to isoniazid (in the absence or presence of
any other drug resistance with the exception of rifampin), and
multidrug resistance (isoniazid resistance in the presence of
rifampin resistance). To assess availability of data, we categorized
countries according to whether, from 1994 to 2009, they reported
data once, twice or three or more times and whether or not they
reported data at a national or sub-national level. We also
examined whether countries had reported any data since 2000
to assess the representativeness of existing data for current
conditions.
We estimated the mean percentages of individuals with these
three types of resistance among three groups: new TB cases (those
that have received less than 1 month of TB treatment at any point
in the past), retreatment TB cases (those that have at least 1 month
of TB treatment at any point in the past), and all TB cases (i.e.
combined category of new and retreatment cases). We estimated
the percentage with each of the three types of resistance among
these three groups using the most recent information from all
countries that reported data between 1994 and 2009 and weighted
by population size. Estimates were based on countrywide data
where available and from sub-national surveys where national
estimates were not reported. We then used these national/
subnational estimates to produce estimates by WHO region and
for the world. Since all estimates were weighted by population size,
we excluded sub-national surveys conducted in areas where
population size was not reported from these aggregated estimates.
Results were based on reported data only; no estimates were made
for countries that did not report data.
We also produced mean estimates for countries with high
prevalence of HIV among adults, which we defined as those
countries with an estimated adult seroprevalence of 2% or higher
in 2009 [15].
For most analyses in this report, we report the percentage with
each type of resistance; however, to better characterize time trends
in resistance, we also provide estimated trends in the number of TB
cases with resistance. Each measure provides useful information
and considering both together facilitates accurate interpretation of
changes over time. For example, if the incidences of both drug-
resistant and drug-sensitive TB are falling, but resistant disease is
declining at a slower pace, then the percentage of incident cases
with resistance will increase over time despite an otherwise
promising reduction in burden [16].
We estimated the number of new TB cases with INH-R by
multiplying our estimated percentage of new TB cases with INH-
R by the number of new notified TB cases in that setting. Per
capita rates were calculated based on reported population size.
Because the estimated numbers of new cases are considered more
reliable, we did not estimate the incidence of drug-resistance
among cases presenting for retreatment.
We estimated time trends for each setting that reported data at
least three times between 1994 and 2009. We used a weighted least
squares regression and modelled the percentage of new TB cases
with INH-R using year as the explanatory variable and weighted
by the number of cases tested in each year. We looked for a
significant linear effect of year to identify increasing or decreasing
trends (using a p-value of 0.1 to conservatively ensure that any
changes were detected). Note that all estimated changes in the
percentage of cases with resistance were absolute changes, i.e.
from a starting point of 5%, a 5% increase represents an increase
to 10%. We performed similar analyses for the number of new TB
cases with INH-R per 100,000 population, weighting by the
population each year in this case. To further explore trends in
INH-R, we subdivided the numbers of new TB cases with INH-R
per 100,000 population into those with INH-R but not rifampin
resistance and those with MDR. In this analysis, we only examined
numbers and not percentages since changes in numbers have
clearer relevance for the burden of disease over time. Note that
areas with non-significant time trends may still report substantial
differences from one time point to the next. However, our aim
here was to identify areas where there is evidence that INH-R
levels are changing consistently over time.
SAS version 9.2 and R version 2.11.1 were used for all analyses.
Results
Data availability
Since 1994, 106 countries/territories have provided national
data on INH-R among all incident TB cases (Figure 1). Including
countries reporting only sub-national data, 131 different settings
provided data on all incident cases, of which 39% provided
sufficient data to estimate time trends (3 or more data points). Data
provided on INH-R among all TB cases cover 56% of the world’s
population.
Isoniazid resistance - global estimates and geographic
variation
The estimated percentage of incident TB cases with INH-R was
substantially higher in the Eastern European region than any other
WHO region (Figure 2) at 44.9% (95% CI: 34.0%, 55.8%). Of
new cases, 33.5% (95% CI: 24.8%, 42.2%) had INH-R and 61.4%
(95% CI: 53.6%, 69.2%) of retreatment cases had INH-R. A single
global estimate, therefore, seemed inappropriate and we focus
instead on the Eastern European region and all other regions
separately. All other regions combined reported an estimated
13.9% (95% CI: 12.6%, 15.2%) of incident cases with INH-R
(10.7% (95% CI: 9.8%, 11.7%) among new TB cases and 29.0%
(95% CI: 26.4%, 31.5%) among retreatment cases). The Western
and Central European countries had the lowest percentages of
INH-R among all incident cases at 6.4% and 17.0% among new
and retreatment cases respectively closely followed by the African
region at 6.3% and 20.0% (Figure 2).
The highest percentages of INH-R among new TB cases
(40-43%) were found in Kazakhstan, Baku City in Azerbaijan and
Isoniazid Resistant Tuberculosis
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European regions, China, Vietnam, the Dominican Republic and
parts of India reported between 15% and 20% of new TB cases
with INH-R. Among retreatment cases, the highest percentages
with INH-R were in Baku City in Azerbaijan (80%) and some
Russian Oblasts (.70%). Outside the Eastern European region,
the highest percentages were in Lebanon (75%), Sierra Leone
(62%) and parts of China (45–55%).
Isoniazid resistance – time trends
Due to the scarcity of time series data, it was not possible to
assess global or regional trends in INH-R TB. However, time
series analysis was possible for 51 and 46 settings that reported
data on INH-R in new and retreatment TB cases respectively at
least three times between 1994 and 2009. Here we highlight results
for settings with particularly strong trends and/or substantial
estimated annual changes (Figure 3). For further illustration in
Figure 4(, we show more detailed time trends for a) Botswana, a
country with high HIV prevalence that is currently increasing
implementation of IPT and (b) Latvia, a country with a large
burden of drug resistant TB that has made substantial commit-
ments to the control of drug resistance.
Increasing percentages and numbers of new TB cases
with INH-R. Both the estimated percentage and number of new
TB cases with INH-R per 100,000 increased significantly in the
Republic of Korea and Botswana (estimated annual increase of 2
cases per 100,000 in Botswana, Figure 4a). In the Russian
Federation, the percentage of new TB cases with INH-R in
Arkhangelsk Oblast increased from 2002–05 with an estimated
absolute annualincreaseof5.0%(i.e. 5 percentage pointseachyear).
Increasing percentages but no consistent linear trend in
numbers of new TB cases with INH-R. The estimated
percentage of new cases with INH-R increased in Peru, Canada,
Finland and France while the estimated number of new TB cases
with INH-R per 100,000 showed no consistent linear trend. In
Oman, the percentage of new cases with INH-R has increased by
an estimated 1.25% annually since 2004 (i.e. an absolute increase
of 1.25 percentage points annually).
Decreasing trends in percentages and/or numbers of new
TB cases with INH-R. The estimated percentage of new cases
with INH-R decreased in Israel (1.0% absolute annual decrease)
and in Hong Kong although there has been a slight increase
observed between 2007 and 2009. There have been steady
declines in the estimated number of new TB cases with INH-R per
100,000 in Latvia and Lithuania (estimated annual decreases of
0.9 and 0.4 cases per 100,000 respectively, Figure 4b) and also in
Belgium and Portugal.
Isoniazid resistance – with and without rifampin
resistance
Subdividing the number of new TB cases with INH-R into
those with MDR and those with INH-R without rifampin
resistance aids understanding of underlying mechanisms for
observed trends in INH-R TB.
In Figure 5, we show those settings that have reported changes
in the estimated number of new TB cases with MDR and those
with INHR without rifampin resistance. In some settings,
changes in INH-R appear to be driven primarily by changes
in MDR and in others by changes in INH-R without rifampin
resistance.
Figure 1. Percentage of incident TB cases with isoniazid resistance. World map showing the percentage of incident TB cases with isoniazid
resistance (INH-R) from the most recent survey in each setting in three time periods: (a) 1994-1999, (b) 2000-2004, (c) 2005-2009. Grey areas indicate
those that did not report national data in the time period in question.
doi:10.1371/journal.pone.0022927.g001
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Of the 29 countries reporting HIV prevalence of 2% or
more[15], 14 (48%) have reported data on INH-R in new and
retreatment cases. Two provided data only at a sub-national level
and 3 of those providing national data did so only before 2000.
Among those countries reporting HIV prevalence of 2% or
more and reporting nationwide data, 7.3% (95% CI: 5.5%, 9.1%)
of all incident TB cases had INH-R (6.5% of new cases and 17.6%
of retreatment cases). Botswana was the only setting in this group
that reported time series data (3 or more data points); it has seen
increasing trends in INH-R in new cases (Figure 4a).
Discussion
There is considerable geographic heterogeneity in the percent-
age of TB cases with resistance to isoniazid. In the Eastern
European WHO region, nearly half of incident TB cases have
INH-R; one in three new cases have INH-R (indicating the extent
of transmission of this type of resistance) and 60% of retreatment
cases. In the rest of the world, around one in seven incident TB
cases have resistance to this important first line drug.
Data on INH-R in TB cases have been provided for 131 settings
since 1994 representing just over half of the world’s population.
However, many of these areas have provided data at only a single
time point, sub-nationally or more than a decade ago. Only
around 40% of these settings have provided data at 3 or more time
points between 1994 and 2009 limiting our ability to assess trends.
Surveillance for INH-R is important because resistance to
isoniazid increases the probability of acquiring resistance to other
drugs including rifampin and thereby MDR-TB [6,7,17]. The
presence of INH-R also compromises the likelihood of having a
successful outcome with treatment [6,7,17]. Testing and reporting
is currently not sufficiently frequent to monitor the levels or trends
in isoniazid resistance for many countries.
Monitoring of INH-R is especially important in places where
IPT may be initiated or its coverage extended. In countries with
HIV prevalence of 2% or more, the percentage of incident cases
with INH-R is 7.3%; this is lower than the overall average for
countries reporting data to the WHO (even excluding Eastern
Europe), but does suggest that a substantial number of individuals
receiving IPT may already be resistant to this drug. We also note
that there is limited availability of TB resistance data from high
Figure 2. Percentage of all, new and retreatment TB cases with isoniazid resistance by WHO region. Percentage of (a) all TB cases, (b)
new TB cases and (c) retreatment TB cases with any resistance to isoniazid, resistance to isoniazid but not rifampin and multi-drug resistance by WHO
region (AFR= African region, AMR= region for the Americas, EMR= Eastern Mediterranean region, EUR E= Eastern European region, EUR WC=
Western and Central European regions, SEAR= South-East Asian region, WPR= Western Pacific region). Countrywide data only from the most recent
survey available 1994-2009. Blue bars represent any isoniazid resistance, red bars represent isoniazid resistance without rifampin resistance and white
bars represent multi-drug resistance.
doi:10.1371/journal.pone.0022927.g002
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with adult HIV seroprevalence of at least 2% have reported
national data since 2000. Botswana, the one country where time
trend analysis is possible, has had an apparent increase in both the
percentage and number of new TB cases with INH-R; this is
appears to be mostly due to rising MDR and is concerning because
this is the African setting in which IPT roll-out is being adopted
most rapidly [19,20,21]. The evidence is compelling that IPT
could reduce incidence of active disease substantially in these high
HIV prevalence areas [8] but the presence of INH-R may reduce
these expected benefits. Continued monitoring of INH-R in areas
in which IPT is being utilized will be essential for ensuring the
effectiveness of preventive therapy.
Given that INH-R increases the likelihood of acquiring
additional resistance during standard TB treatment, monitoring
the burden of INH-R (and INH-R without rifampin resistance
in particular) may provide important early warnings for areas
vulnerable to increases in MDRTB. Figure 5- shows the settings
in which numbers of TB cases with INHR without rifampin
resistance are increasing. During the study period, the number
of new TB cases with this type of resistance increased in a
number of geographically disparate settings such as the Tomsk
Oblast in the Russian Federation, the Republic of Korea,
Oman and the USA. Such trends are concerning not only for
the impact on treatment outcomes but also the potential
subsequent implications for MDRTB. It should also be noted
that, while not the main focus of this paper, Figure 5 highlights
a number of countries with increasing numbers of MDRTB
cases per capita.
Within Eastern Europe - the region with the highest percentage
of incident cases with INH-R - the current situation is worrisome,
but the outlook is improving in some locations. The number of
new TB cases with INH-R among new cases is declining, for
example, in Lithuania and Latvia (Figure 4b). In the latter,
reductions in the numbers of incident TB cases with drug
resistance have been linked to several factors including improved
case detection, individualized treatment and case management
strategies and better quality drug supply and distribution
minimising interruptions to treatment [22].
In settings where the current burden of INH-resistance is
currently low, upward trends should be viewed with concern. Such
trends were apparent in countries such as Botswana, Republic of
Korea and Peru. There are also parts of Western Europe, such as
France, where despite decreases in TB notifications [23], the
percentage and/or number of new TB cases with INH-R is
increasing.
There are also some clear success stories such as Lithuania and
Latvia, as described above and some Western European countries
that have seen a decline in numbers of cases with INH-R without
rifampin resistance such as Belgium, Switzerland and Denmark. In
other locations, the percentage of new cases with INH-R is on a
downward trend such as in Hong Kong where high case detection
rates and a low proportion of cases requiring retreatment are
indicative of a well functioning TB control programme [24]. In
Portugal, the number of new TB cases with INH-R has declined
and this may at least partially reflect the effect of efforts to improve
case detection and treatment completion among individuals
struggling with drug addiction, a risk group with high rates of
treatment abandonment [25].
These data raise further questions: at the population level, does
increasing incidence of INH-R precede increasing incidence of
MDR? Does INH-R increase – or decrease – more rapidly over
time than MDR? More detailed resistance data, especially those
that include repeated sampling or surveillance in high TB
incidence countries will help address some of these important
questions.
Figure 3. Linear trends in isoniazid resistance (INH-R) among new TB cases. We estimated trends in the percentage of new TB cases with
INH-R and the estimated number of new TB cases with INH-R per 100,000 population. Settings are grouped by any linear trend (p,0.1) found
(‘‘down’’ or ‘‘up’’) or ‘‘no consistent linear trend’’ if no linear trend was found. RF=Russian Federation.
doi:10.1371/journal.pone.0022927.g003
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markedly reduce the turn around time for testing. However, since
there is a far greater understanding of the mutations that are
associated with rifampin resistance than isoniazid resistance [26],
sensitivity for detecting INH-R with these methods is currently far
lower than for rifampin resistance [27]. In fact, since resistance to
rifampin in most settings is usually accompanied by INH-R, some
tests that are being used to screen for MDRTB only test for
rifampin resistance [28,29]. Unless additional mutations associated
with isoniazid resistance are identified to increase the sensitivity of
these molecular tests, there is a possibility that surveillance and
detection of INH-R will decrease rather than increase in the
future.
The regional averages that we have provided are from countries
that have reported data and therefore may not be representative of
areas in which data were not available (Figure 2). Through this
analysis of existing population representative data on INH-R TB,
we have identified areas of concern as well as encouraging
examples of settings with declining burdens of isoniazid resistance.
A key additional finding is the absence of recent drug resistance
Figure 4. Percentage and number of new TB cases with isoniazid-resistant TB in (a) Botswana and (b) Latvia. Markers indicate reported
data. The numbers with INH-R per 100,000 population (pink triangles) are also subdivided into those with MDR (red ‘+’ symbols) and those with INH-R
without rifampin resistance (green ‘X’ symbols). Data points for the percentage of TB cases with INH-R are marked by blue squares. Lines indicate
fitted linear trends and are only displayed where a significant linear trend was found (p,0.1). The colour of the line matches the colour of the data
points to which the linear trend is fitted. Note that scales are different between (a) and (b) and that there are two y-axes, one for the percentage and
one for the number of TB cases with INH-R per 100,000 population.
doi:10.1371/journal.pone.0022927.g004
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most effectively to the threat of drug-resistant TB requires an
understanding of the magnitude of this problem, we encourage
continued and increased financing of these essential monitoring
activities.
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